GLPwatch

Bariatric Surgery Combined With GLP-1 Receptor Agonists Study

NCT07336862 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether combining bariatric surgery with GLP-1 receptor agonists helps people with obesity lose weight.

Status Recruiting Currently enrolling participants.
Phase Phase1, Phase2
Type Interventional (clinical trial)
Design Non-randomized, open-label (no blinding) treatment study
Participants 200 people Planned (estimated).
Who can join Ages 18–60 · all sexes
Timeline Started 2024-01 · est. completion 2027-12
Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07336862 ↗

Description as written by the study sponsor.

Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits. This study investigates the efficacy and safety of bariatric surgery combined with GLP-1 receptor agonist adjuvant therapy for severe obesity.

Treatments tested

Main thing measuredthe Percentage of weight loss
SponsorChina-Japan Friendship Hospital
Conditions studiedObesity
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07336862 ↗